Lyon: CSPC PHARMA (01093) stock price surges sharply, driven by the successful Phase 3 results of Moderna's mRNA cancer vaccine.

Lyon released a research report stating that CSPC PHARMA (01093) saw its stock price surge over 15% this morning, primarily driven by the positive top-line results from the INTerpath-001 Phase III clinical trial of the personalized mRNA cancer therapy intismeran (in combination with Keytruda) by Moderna (MRNA) and Merck (MRK) for melanoma stages IIB to IV. This represents the first time a personalized mRNA cancer therapy has achieved positive signals in a Phase III trial globally. Lyon noted that this therapy customizes mRNA encoding up to 34 new antigens for patients through tumor sequencing, aiming to amplify tumor-specific T cell immunity when combined with PD-1 inhibitors. CSPC PHARMA is one of the most technologically advanced companies among domestic mRNA vaccine developers, having validated its platform technology with the approval of China's first COVID-19 mRNA vaccine, "DunTai," which was granted marketing authorization in 2023. The groups leading therapeutic vaccine project includes SYS6017, an HPV mRNA therapeutic vaccine targeting high-grade squamous intraepithelial lesions (HSIL) associated with HPV types 16/18, while other earlier-stage therapeutic cancer vaccines are also in preclinical research stages.